- Adjusted gross profit margin was 77.6%, down from 80% last year due to manufacturing expenses and foreign exchange impacts.
- Adjusted operating profit margin improved to 28.2% benefiting from strong sales and deferred spending, with full year guidance at 27% to 28%.
- Cash and cash equivalents stood at approximately $3 billion with $1 billion remaining in share repurchase authorization.
- Edwards Lifesciences reported second quarter 2025 total sales of $1.53 billion, growing 10.6% year-over-year, driven by broad-based growth across structural heart therapies.
- GAAP EPS was $0.57 including a onetime charge; adjusted EPS was $0.67, beating expectations.
- Research and development expenses were $276 million or 18% of sales, reflecting strategic prioritization of structural heart investments.
- Selling, general and administrative expenses were $502 million or 32.8% of sales, up from $448 million prior year, with increased spending expected in H2.
- Surgical product group sales increased 6.8% to $267 million, supported by positive procedure growth and new product approvals.
- TAVR sales reached $1.1 billion, up 7.8% globally with stable competitive positioning and pricing.
- TMTT sales grew 57% to $133 million, reflecting strong adoption of PASCAL, EVOQUE, and the addition of SAPIEN M3.
Related items and other data are not available for this feed item.
Dafinchi